262 related articles for article (PubMed ID: 24912600)
1. Translational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.
Nagel-Wolfrum K; Möller F; Penner I; Wolfrum U
Vis Neurosci; 2014 Sep; 31(4-5):309-16. PubMed ID: 24912600
[TBL] [Abstract][Full Text] [Related]
2. A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation.
Goldmann T; Overlack N; Möller F; Belakhov V; van Wyk M; Baasov T; Wolfrum U; Nagel-Wolfrum K
EMBO Mol Med; 2012 Nov; 4(11):1186-99. PubMed ID: 23027640
[TBL] [Abstract][Full Text] [Related]
3. Strategies against Nonsense: Oxadiazoles as Translational Readthrough-Inducing Drugs (TRIDs).
Campofelice A; Lentini L; Di Leonardo A; Melfi R; Tutone M; Pace A; Pibiri I
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31284579
[TBL] [Abstract][Full Text] [Related]
4. Ataluren for the Treatment of Usher Syndrome 2A Caused by Nonsense Mutations.
Samanta A; Stingl K; Kohl S; Ries J; Linnert J; Nagel-Wolfrum K
Int J Mol Sci; 2019 Dec; 20(24):. PubMed ID: 31842393
[TBL] [Abstract][Full Text] [Related]
5. Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through.
Brumm H; Mühlhaus J; Bolze F; Scherag S; Hinney A; Hebebrand J; Wiegand S; Klingenspor M; Grüters A; Krude H; Biebermann H
Obesity (Silver Spring); 2012 May; 20(5):1074-81. PubMed ID: 21738238
[TBL] [Abstract][Full Text] [Related]
6. Targeting Nonsense Mutations in Diseases with Translational Read-Through-Inducing Drugs (TRIDs).
Nagel-Wolfrum K; Möller F; Penner I; Baasov T; Wolfrum U
BioDrugs; 2016 Apr; 30(2):49-74. PubMed ID: 26886021
[TBL] [Abstract][Full Text] [Related]
7. Pharmaceuticals Promoting Premature Termination Codon Readthrough: Progress in Development.
Li S; Li J; Shi W; Nie Z; Zhang S; Ma F; Hu J; Chen J; Li P; Xie X
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371567
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceuticals targeting nonsense mutations in genetic diseases: progress in development.
Rowe SM; Clancy JP
BioDrugs; 2009; 23(3):165-74. PubMed ID: 19627168
[TBL] [Abstract][Full Text] [Related]
9. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C.
Goldmann T; Overlack N; Wolfrum U; Nagel-Wolfrum K
Hum Gene Ther; 2011 May; 22(5):537-47. PubMed ID: 21235327
[TBL] [Abstract][Full Text] [Related]
10. Cancer syndromes and therapy by stop-codon readthrough.
Bordeira-Carriço R; Pêgo AP; Santos M; Oliveira C
Trends Mol Med; 2012 Nov; 18(11):667-78. PubMed ID: 23044248
[TBL] [Abstract][Full Text] [Related]
11. Ataluren and aminoglycosides stimulate read-through of nonsense codons by orthogonal mechanisms.
Ng MY; Li H; Ghelfi MD; Goldman YE; Cooperman BS
Proc Natl Acad Sci U S A; 2021 Jan; 118(2):. PubMed ID: 33414181
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of premature stop codon readthrough in the CFTR gene by Ataluren (PTC124) derivatives.
Pibiri I; Lentini L; Melfi R; Gallucci G; Pace A; Spinello A; Barone G; Di Leonardo A
Eur J Med Chem; 2015 Aug; 101():236-44. PubMed ID: 26142488
[TBL] [Abstract][Full Text] [Related]
13. Mechanism and evidence of nonsense suppression therapy for genetic eye disorders.
Richardson R; Smart M; Tracey-White D; Webster AR; Moosajee M
Exp Eye Res; 2017 Feb; 155():24-37. PubMed ID: 28065590
[TBL] [Abstract][Full Text] [Related]
14. Read-through strategies for suppression of nonsense mutations in Duchenne/ Becker muscular dystrophy: aminoglycosides and ataluren (PTC124).
Finkel RS
J Child Neurol; 2010 Sep; 25(9):1158-64. PubMed ID: 20519671
[TBL] [Abstract][Full Text] [Related]
15. Aminoglycosides, but not PTC124 (Ataluren), rescue nonsense mutations in the leptin receptor and in luciferase reporter genes.
Bolze F; Mocek S; Zimmermann A; Klingenspor M
Sci Rep; 2017 Apr; 7(1):1020. PubMed ID: 28432296
[TBL] [Abstract][Full Text] [Related]
16. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system.
Keeling KM; Bedwell DM
J Mol Med (Berl); 2002 Jun; 80(6):367-76. PubMed ID: 12072912
[TBL] [Abstract][Full Text] [Related]
17. PTC124 targets genetic disorders caused by nonsense mutations.
Welch EM; Barton ER; Zhuo J; Tomizawa Y; Friesen WJ; Trifillis P; Paushkin S; Patel M; Trotta CR; Hwang S; Wilde RG; Karp G; Takasugi J; Chen G; Jones S; Ren H; Moon YC; Corson D; Turpoff AA; Campbell JA; Conn MM; Khan A; Almstead NG; Hedrick J; Mollin A; Risher N; Weetall M; Yeh S; Branstrom AA; Colacino JM; Babiak J; Ju WD; Hirawat S; Northcutt VJ; Miller LL; Spatrick P; He F; Kawana M; Feng H; Jacobson A; Peltz SW; Sweeney HL
Nature; 2007 May; 447(7140):87-91. PubMed ID: 17450125
[TBL] [Abstract][Full Text] [Related]
18. In vitro read-through of phenylalanine hydroxylase (PAH) nonsense mutations using aminoglycosides: a potential therapy for phenylketonuria.
Ho G; Reichardt J; Christodoulou J
J Inherit Metab Dis; 2013 Nov; 36(6):955-9. PubMed ID: 23532445
[TBL] [Abstract][Full Text] [Related]
19. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina.
Goldmann T; Rebibo-Sabbah A; Overlack N; Nudelman I; Belakhov V; Baasov T; Ben-Yosef T; Wolfrum U; Nagel-Wolfrum K
Invest Ophthalmol Vis Sci; 2010 Dec; 51(12):6671-80. PubMed ID: 20671281
[TBL] [Abstract][Full Text] [Related]
20. Aminoglycoside-induced translational read-through in disease: overcoming nonsense mutations by pharmacogenetic therapy.
Zingman LV; Park S; Olson TM; Alekseev AE; Terzic A
Clin Pharmacol Ther; 2007 Jan; 81(1):99-103. PubMed ID: 17186006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
